Mechanistic modeling of critical network transitions in neuroinflammation

Mechanistic modeling of critical network transitions in neuroinflammation - RELapse-specific biomarker Analysis for paTtern idEntification in Multiple Sclerosis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00038346

Enrollment

192

Registered

2026-05-11

Start date

2026-03-26

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G35.11

Interventions

Group 1: Determination of various biomarkers from the serum of patients with multiple sclerosis at the time of an acute relapse and one and three months later. Magnetic resonance imaging after three m

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Primary diagnosis of relapsing-remitting multiple sclerosis (RRMS) Clinical suspicion of acute relapse or appropriate age, gender, and immunotherapy for patients in the acute relapse group

Exclusion criteria

Exclusion criteria: Secondary progressive multiple sclerosis

Design outcomes

Primary

Measure	Time frame
The aim of the study is to identify a reliable biomarker profile that changes at the time of an acute relapse and after it has subsided. The parameters are measured at the time of inclusion, after one month, and after three to six months. The biomarkers neurofilament (NfL) and glial fibrillary acidic protein (GFAP) are measured, the proteome is examined, and peripheral blood mononuclear cells (PBMCs) are analyzed from blood. To objectively confirm that a relapse has occurred, a MRI check is performed after three months.	—

Measure

Time frame

The aim of the study is to identify a reliable biomarker profile that changes at the time of an acute relapse and after it has subsided. The parameters are measured at the time of inclusion, after one month, and after three to six months. The biomarkers neurofilament (NfL) and glial fibrillary acidic protein (GFAP) are measured, the proteome is examined, and peripheral blood mononuclear cells (PBMCs) are analyzed from blood. To objectively confirm that a relapse has occurred, a MRI check is performed after three months.

—

Countries

Germany

Contacts

Public ContactStefan Bittner

Universitätsmedizin Mainz, Klinik für Neurologie

stefan.bittner@unimedizin-main.de06131 17 7156

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 11, 2026